Nasdaq GlobeNewswire

XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board

Del

AUSTIN, Texas, Sept. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) is pleased to announce the appointment of Peter Libby, MD to its Scientific Advisory Board (SAB). Dr. Libby will work with XBiotech to help further develop its clinical and research programs including studies evaluating bermekimab’s potential in improving patient outcomes by reducing risk of heart attack or strokes.

Dr. Libby’s group recently published their discovery that a crucial mechanism behind heart attacks and stroke may involve inflammation that is targeted by the Company’s antibody, bermekimab. Bermekimab targets a pro-inflammatory factor known as Interleukin-1 alpha.  The FDA granted fast track approval for bermekimab in cardiovascular medicine and the Company hopes to now further its clinical development of bermekimab as a prophylaxis in patients at high risk for heart attack and stroke. Dr. Libby will be part of a team that will direct the use of bermekimab to reduce the risk of cardiovascular events.

Dr. Libby commented:  “Inflammatory pathways participate causally in cardiovascular diseases, and recent research has demonstrated that targeting inflammation can reduce the risk of recurrent heart attacks.  I am eager to continue to explore rigorously the efficacy of blocking these pathways in limiting the ravages of  cardiovascular and kidney diseases both experimentally and in patients.”

John Simard, XBiotech’s President & CEO, stated, “We are elated to have Dr. Libby join our team and to further the development of bermekimab in areas where substantial unmet need exists for the most vulnerable patients at risk for heart attacks and strokes.”

The Company recently announced the publication of the research findings led by Dr. Libby which implicate IL-1⍺ as a potential contributor to life threatening heart attacks and strokes. Dr. Libby’s findings are published online in a journal of the American Heart Association (AHA). The article titled,  Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1α and Cathepsin G , was featured in the August print issue of Arteriosclerosis, Thrombosis, and Vascular Biology.

About Peter Libby, M.D.
Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School (HMS).  His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis.  Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials. Dr. Libby is continually named a top cardiologist. His research has received funding from the American Heart Association and National Institutes of Health. Dr. Libby has received world-wide research recognitions including the highest research awards from the American Heart Association and American College of Cardiology, the Gold Medal of the European Society of Cardiology, the Anitchkow award from the European Atherosclerosis Society, The Ernst Jung Gold Medal for Medicine, and the Earl Benditt award for vascular biology. The author of over 400 original peer-reviewed publications, some 450 reviews, chapters, or other publications, Dr. Libby also serves as an Editor of the leading textbook of cardiovascular medicine Braunwald’s Heart Disease. Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and honorary doctorates from the University of Lille and Université Laval.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech is currently advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech is also leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

 

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Lehman Brothers UK Capital Funding V LP: Notice to the Holders of the Preferred Securities19.11.2018 18:03Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TEMP: 91SI NOTICE TO THE HOLDERS OF: USD 500,000,000 FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP V ECAPS") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING V LP ("LP V") ISIN: XS0301813522 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP V ECAPS THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP V and the LP V ECAPS. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8119H_1-2018-11-19.pdf If you have any difficulties in openin

Lehman Brothers UK Capital Funding LP: Notice to the Holders of the Preferred Securities19.11.2018 17:53Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- NOTICE TO THE HOLDERS OF: EUR 225,000,000 FIXED RATE TO CMS-LINKED GUARANTEED NON-VOTING, NON-CUMULATIVE PERPETUAL PREFERRED SECURITIES ("LP I Securities") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING LP ("LP I") ISIN: XS0215349357 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP I SECURITIES THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP I and the LP I Securities. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8123H_1-2018-11-19.pdf If

Lehman Brothers UK Capital Funding IV LP: Notice to the Holders of the Preferred Securities19.11.2018 17:46Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Amsterdam Stock Exchange: 49AC NOTICE TO THE HOLDERS OF: EUR 200,000,000 EURO FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP IV ECAPS") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING IV LP ("LP IV") ISIN: XS0282978666 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP IV ECAPS THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP IV and the LP IV ECAPS. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8115H_1-2018-11-19.pdf If you

Algeco Announces Third Quarter 2018 Financial Results Conference Call19.11.2018 16:04Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its third quarter 2018 financial results conference call on Monday 26 November 2018 at 3:00pm GMT (10:00 a.m., Eastern Time). To access the call, please dial: UK: +44 3333000804 or 08003589473 (UK toll free) US: +1 6319131422 or +1 855 85 70686 (US toll free) and enter participant PIN code 84969282# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to https://event.on24.com/wcc/r/1884864/AA4F091A2F921FE451DDBD688F19B26F. Please enter your name, email address and company to join the call. The customer service team can be rea

Bombardier to supply 19 OMNEO Premium trains for the Hauts-de-France region’s intercity lines19.11.2018 15:31Pressemelding

OMNEO Premium will provide about 25% more seating capacity to intercity travelers between Paris and the Hauts-de-France region A comfortable double-deck train offering new features such as newly-designed spacious seats, easier platform access and ample baggage space BERLIN, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/683009f7-6c0e-4ab2-8800-5bb87399c7e0 Mobility technology leader Bombardier Transportation announced today that it received an order for 19 BOMBARDIER OMNEO Premium double-deck trains from the French National Railway Corporation, Société nationale des chemins de fer français (SNCF) on behalf of the Hauts-de-France region. This call-off order is part of the contract signed in 2010 with SNCF to provide up to 860 double deck-trains to French regions and is valued at approximately 256 million euro ($291 million US), including price esc

CP Kelco Announces Plans to Invest in Specialty Biogums Capabilities and Capacity Expansion19.11.2018 14:15Pressemelding

ATLANTA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In response to the strong global demand for specialty Biogums products, CP Kelco announced today its plans to invest in building capabilities and expanding production capacity. As a leading global producer and innovator of hydrocolloid solutions, CP Kelco is reinforcing its commitment to three Biogums product lines – gellan gum, specialty xanthan gum and diutan gum – through these key operational initiatives: Adding gellan gum production capabilities in the company’s Wulian, China facility to support growth in the Asia Pacific region; Expanding the overall capacity of the Wulian, China facility to support growth across all three specialty Biogums product lines; and Expanding the recently added gellan gum production capacity in the company’s Okmulgee, Oklahoma, USA facility. In addition to the planned investments in new production capabilities and capacity, CP Kelco is equally committed to ensuring its Biogums products meet the high standards o

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom